Update 08/02/21 12:22 PM
BIG NEWS OUT: Update on their website in regards to merger closing. In addition to that a Collab – UPMC & Pitt Develop New Cancer Immunotherapy
PITTSBURGH – A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh School of Medicine and New Jersey-based biotechnology company Avalon GloboCare Corp. aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks. Full article: https://www.upmc.com/media/news/080221-Hillman-Avalon-CAR-Therapy
We will have more on this in the full report tomorrow.
An Accretive Acquisition Including Valuable Cell Technology Could Make Avalon GloboCare (AVCO) a Leader in the Cell Biology Sector
Technical Setting up for a Swing
Good day everyone,
We are initiating coverage on Avalon GloboCare Corp. (NASDAQ: AVCO), a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications.
Current price $.9824/share
Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.
We believe Avalon is an up-and-coming Celltech company with the potential to become a force in the sector and presents with a solid indication of near to mid-term upswing. AVCO looks to be an opportunity for entry into the fast-growing cell biology sector at a value price.
We have included this link to a company slide presentation detailing their developmental and clinical advancements. We urge you to visit this site to gain perspective on the research being done by AVCO and their affiliates in cellular technology.
While AVCO has impressive cellular technology, today, we need to talk about why AVCO shares could run in the near-term. We encourage you to do your due diligence, look at their science, but we feel there could be an imminent upswing here and want to address that.
When we look at the company stock chart we can see that AVCO shares have been sliding into a dip falling below their 50 DMA and 200 DMA of $1.03 and $1.14 respectively. That slide may have ended Wednesday of last week when the shares closed at $.833. At the close of Friday’s session, AVCO shares were at $.9824/share, breaking above the 20 DMA and moving towards the 50 DMA. A break above the 50 DMA this week will no doubt attract lots of technical traders. We believe last week’s gain is just the beginning of a significant upswing and that is why we feel the timing is right here.
AVCO shares hit a high of $1.56/share in mid-June when they announced their intent to acquire Hebei Senlang Biotechnology Co. Ltd., a cell therapy company for 81 million of AVCO common shares (no preferred or warrants). AVCO currently has $1.3M in revenues and Senlang generates revenues estimated at $5-7M for the current fiscal year so the acquisition would be accretive, and Senlang has a broad range of cellular therapy candidates.
Read about the proposed acquisition in this letter to shareholders dated June 28, 2021. The acquisition of ShenlangBio may be a transformative move for AVCO, adding significantly to the company’s value, revenues, and product pipeline.
Avalon was also able to secure approximately USD $30 million from an institutional healthcare investor, in conjunction with the acquisition for an approximately 13.5% equity interest in SenlangBio without warrants or other equity-linked or debt instrument. That $30M creates a substantial cash runway for Avalon’s clinical trials.
The day the acquisition was announced law firms began to seek clients interested in filing suit against AVCO with the main theme being that they may be overpaying for Senlang and citing a lack of information being provided. We believe these possible legal actions may be partly responsible for the dip in the share price. In the long run, the shares traded for Senlang could seem like a bargain and we had no issues finding SEC documents regarding the acquisition:
AVCO only has 27.6M shares in the public float. The acquisition will be dilutive adding 81 million shares to the existing 84 million shares outstanding but may not immediately impact the float. Insiders own 63% of the outstanding shares meaning two things; the acquisition is likely to happen, and the insiders’ shares will be diluted the same as anyone’s. That indicates to us that the benefits of the acquisition outweigh the potential for dilution.
Blackrock, Inc. an institutional investor, owns 1.3% of the company shares (as of 5-7-21)
According to AVCO, the acquisition of Senlang “will significantly enhance Avalon’s capabilities in cell and gene therapy, expanding their therapeutic pipeline by adding 15 autologous and universal (off-the-shelf) cell therapy programs.”
It appears AVCO is getting a lot for its all-stock payment for Senlang. To date, over 300 patients have received one of SenlangBio’s 15 cell therapy candidates through investigator-initiated first-in-human clinical trials. SenlangBio’s clinical trials have demonstrated clinical benefit and favorable safety profiles among patients with solid tumors and hematological malignancies.
SenlangBio, has initiated a first-in-human clinical trial evaluating anti-EphA2 (CAR) T-cell therapy for recurrent glioblastoma. EphA2 is a tumor-associated antigen expressed on glioblastoma cells but not on non-cancerous, normal cells of the brain. The use of this therapy on solid tumors is in its infancy and Shenlang is indicating positive results thus far. Developments in oncology don’t get much bigger than this.
SenlangBio’s intellectual property includes 10 issued patents and 5 patents pending, SenlangBio will bring added capabilities to Avalon with their 16,000 square-foot GMP facility, which supports in-house bio-manufacturing, bioprocessing, and QA/QC processes.
Many of the big pharma companies, such as Astra Zeneca, GlaxoSmithKline, Vertex and Genentech are working in the cell biology area as well as many private companies. We believe that AVCO offers investors a value. In a small public company like AVCO, innovative and nimble, the catalysts and milestones achieved can come quickly and have a greater impact on the company value than big pharma.
The combination of AVCO and SenlangBio should create a significant force in the cellular treatment of oncology indications. We believe the very recent turn around in the Avalon share price is an indicator of a greater near to mid-term swing to the upside for AVCO’s market value. Again, we believe the timing is right.
About Avalon GloboCare Corp.
The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology; and with University of Pittsburgh of the Commonwealth System of Higher Education. It also has a collaboration agreement with the UPMC Hillman Cancer Center to advance the clinical development and production of CAR therapies using FLASH CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
Stay tuned for more on Avalon GloboCare Corp. (AVCO)
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.